The genomic diagnostics company saw revenue rise to $30.14 million from $22.8 million in the comparable quarter a year ago. The result also topped analysts' average estimate of $29.16 million.
Moving forward, Veracyte said it is raising its 2019 annual revenue guidance to a range of $119 million to $122 million from its previous forecast of $117 million to $121 million. Forecasts are for sales of $120.54 million.
Price: 29.61, Change: +0.43, Percent Change: +1.47
|Yum China Holdings' Consensus Projections for Q1, 20...|
|Analysts Trim Exxon Mobil's Q1, 2020, and 2021 Earni...|
|ANSYS Posts Higher-Than-Expected Q4 Earnings, Revenue|
|Forecast for Cimarex Energy's Q1 and Full Year Earni...|
|Analysts' Increase Q1 and 2020 Estimates for Xenia H...|